Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors

被引：0
|
作者：
Zhang, Songling
Zhu, Xiaoxue
Gao, Lei
Qi, Yaling
Jia, Xiao
Li, Yongguo
Guo, Ye
Ding, Yanhua
机构：
[1] First Hosp Jilin Univ, Gynecol & Obstet Ctr, Dept Gynecol Oncol, Changchun, Peoples R China
[2] First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China
[3] First Hosp Jilin Univ, Changchun, Peoples R China
[4] Shanghai Jiatan Pharmatech CO LTD, Shanghai, Peoples R China
[5] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14627
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
    Li, G.
    Huang, A.
    Zhao, Y.
    Li, B.
    Ding, Y.
    Lai, S.
    Zhang, J.
    Zhu, H.
    Li, D.
    Li, Q.
    Jia, X.
    Qi, Y.
    Li, Y.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S553 - S553
  • [2] WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.
    Tang, Wenbo
    Guo, Ye
    Xue, Liqiong
    Peng, Wei
    Ge, Xiaoxiao
    Xue, Junli
    Wei, Wei
    Xu, Juncai
    Li, Yongguo
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Guo, Y.
    Xue, L.
    Tang, W.
    Li, B.
    Zhu, Z.
    Ding, Y.
    Niu, L.
    Jia, Y.
    Jia, X.
    Qi, Y.
    Li, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [4] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [5] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
  • [6] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
    Li, Jin
    Xue, Junli
    Liu, Tianshu
    Feng, Yi
    Xu, Nong
    Huang, Jianjin
    Yin, Yongmei
    Zhang, Jun
    Mou, Haibo
    Shentu, Jiangzhong
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
  • [7] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.
    Li, Jin
    Xu, Nong
    Liu, Tianshu
    Huang, Jianjin
    Yin, Yongmei
    Mou, Haibo
    Zhang, Jun
    Wu, Lihua
    Liu, Zong Liang
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
    Janku, Filip
    Choong, Grace M.
    Opyrchal, Mateusz
    Dowlati, Afshin
    Hierro, Cinta
    Rodon, Jordi
    Wicki, Andreas
    Forster, Martin D.
    Blagden, Sarah P.
    Yin, Jun
    Reid, Joel M.
    Muller, Helene
    Cmiljanovic, Natasa
    Cmiljanovic, Vladimir
    Adjei, Alex A.
    CANCERS, 2024, 16 (06)
  • [9] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    Grilley-Olson, J. E.
    Bedard, P. L.
    Fasolo, A.
    Cornfeld, M.
    Cartee, L.
    Razak, A. R. Abdul
    Stayner, L. -A.
    Wu, Y.
    Greenwood, R.
    Singh, R.
    Lee, C. B.
    Bendell, J.
    Burris, H. A.
    Del Conte, G.
    Sessa, C.
    Infante, J. R.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 740 - 749
  • [10] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
12345